(NASDAQ: PGEN) Precigen's forecast annual revenue growth rate of 260.45% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Precigen's revenue in 2025 is $4,201,000.On average, 2 Wall Street analysts forecast PGEN's revenue for 2025 to be $2,653,668,739, with the lowest PGEN revenue forecast at $838,311,370, and the highest PGEN revenue forecast at $4,469,026,108. On average, 2 Wall Street analysts forecast PGEN's revenue for 2026 to be $19,920,226,349, with the lowest PGEN revenue forecast at $3,182,041,047, and the highest PGEN revenue forecast at $36,658,411,651.
In 2027, PGEN is forecast to generate $66,424,368,902 in revenue, with the lowest revenue forecast at $66,424,368,902 and the highest revenue forecast at $66,424,368,902.